Allergy Treatment Market Research Report Information By Type (Eye Allergy, Rhinitis, Asthma, Skin Allergy, Food Allergy, Other Allergies), By Treatment (Anti-allergy Drugs, Immunotherapy), By Region (North America, Europe, Asia-Pacific, And Rest Of The World) –Market Forecast Till 2032

Global Allergy Treatment Market Overview

Allergy Treatment Market Size was valued at USD 21.2 Billion in 2022. The allergy treatment market industry is projected to grow from USD 22.49 Billion in 2023 to USD 36.12 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 6.10% during the forecast period (2023 - 2032). The increasing prevalence of various forms of allergies and the growing geriatric population are the key market drivers enhancing the market growth.

Source: Secondary Research, Primary Research, MRFR Database and Analyst Review

Allergy Treatment Market Trends

• Personalized immunotherapy approaches are driving market growth

A notable trend in the allergy treatment market is the increasing emphasis on personalized immunotherapy approaches. Traditional allergy treatments often involve generic interventions, but there is a growing shift towards tailoring treatments based on individual patient profiles, including specific allergens and immune responses. Personalized immunotherapy, such as allergen immunotherapy (AIT), aims to address the root cause of allergies, providing more targeted and effective long-term relief. This trend aligns with advancements in precision medicine, allowing for customized allergy treatments that better cater to the unique sensitivities of each patient. This factor drives the market CAGR.

Additionally, in the allergy treatment landscape, there is a distinct trend towards the development and utilization of biologics for severe allergies. Biologics, derived from living organisms, target specific immune pathways involved in allergic reactions. These innovative therapies are particularly effective for severe allergic conditions like asthma and allergic rhinitis. The trend reflects a growing recognition of the need for more potent and targeted interventions, especially for patients with challenging and debilitating allergy symptoms. Biologics offer a promising avenue for achieving improved symptom control and enhancing the quality of life for individuals dealing with severe allergies.

The allergy treatment market is witnessing a trend towards the integration of digital health solutions to enhance patient management and treatment outcomes. Mobile applications, telemedicine platforms, and wearable devices are increasingly utilized to monitor allergy symptoms, track medication adherence, and provide real-time support. This trend not only improves patient engagement but also facilitates more precise data collection for healthcare professionals to tailor treatment plans. The integration of digital health solutions aligns with the broader trend of incorporating technology to streamline and optimize healthcare delivery, fostering a more patient-centric and efficient approach in the field of allergy treatment. For instance, in 2020, the FDA approved its first drug to treat peanut allergy among children in California. Peanut allergy affects the immune system in children. Hence, the adoption of Palforzia prevents such responses from occurring. This factor is also likely to lead to market growth. The key players are performing a major role in the market by focusing on the consumers' desires. Thus, driving the allergy treatment market revenue.

Allergy Treatment Market Segment Insights

• Allergy Treatment Type Insights

The allergy treatment market segmentation, based on Type, includes Eye Allergy, Rhinitis, Asthma, Skin Allergy, Food Allergy, and Other Allergies. The dominant category is Rhinitis, encompassing allergic reactions affecting the nasal passages, sinuses, and throat. Rhinitis is prevalent globally, and its treatment often involves a combination of antihistamines, decongestants, and nasal corticosteroids. Meanwhile, the fastest-growing category is Food Allergy, fueled by an increasing awareness of and diagnosis rates for food-related allergic reactions. With a rising prevalence of food allergies and a heightened focus on allergen avoidance, there is a growing demand for innovative treatments and interventions in the food allergy category, driving its rapid growth within the allergy treatment market.

Allergy treatment Insights

The allergy treatment market segmentation, based on Treatment, includes Anti-allergy Drugs and immunotherapy. The dominant category is Anti-allergy Drugs, including antihistamines, decongestants, corticosteroids, and other medications designed to alleviate allergy symptoms rapidly. Anti-allergy drugs are widely prescribed for various allergic conditions, offering quick relief from symptoms such as sneezing, itching, and congestion. Meanwhile, the fastest-growing category is Immunotherapy, characterized by allergen-specific treatments that aim to modify the immune response and provide long-term relief. Immunotherapy, particularly subcutaneous and sublingual forms, is gaining popularity due to its disease-modifying potential, offering sustained benefits and addressing the underlying causes of allergies.

Figure 1: Allergy Treatment Market, by Treatment, 2022 & 2032 (USD Billion)

Source: Secondary Research, Primary Research, MRFR Database and Analyst Review

Allergy treatment Regional Insights

By region, the study provides the market insights into North America, Europe, Asia-Pacific, and the Rest of the World. The North American allergy treatment market area will dominate this market, owing to the robust healthcare infrastructure in North America, with advanced medical facilities and a high level of healthcare expenditure, facilitating widespread access to allergy diagnostics and treatments. In addition, the growing number of established health clubs and fitness facilities will boost market growth in this region.

Further, the major countries studied in the market report are the US, Canada, Germany, France, the UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.

Figure 2: ALLERGY TREATMENT MARKET SHARE BY REGION 2022 (USD Billion)

Source: Secondary Research, Primary Research, MRFR Database and Analyst Review

Europe's allergy treatment market accounts for the second-largest market share due to exhibits a high prevalence of allergies, encompassing respiratory allergies, skin allergies, and food allergies, among others. Further, the German allergy treatment market held the largest market share, and the UK allergy treatment market was the fastest-growing market in the European region.

The Asia-Pacific Allergy Treatment Market is expected to grow at the fastest CAGR from 2023 to 2032. This is due to the increasing population and urbanization contributing to higher exposure to environmental allergens, leading to a rise in allergic conditions. Moreover, China’s allergy treatment market held the largest market share, and the Indian allergy treatment market was the fastest-growing market in the Asia-Pacific region.

Allergy treatment Key Market Players & Competitive Insights

Leading market players are investing heavily in research and development in order to expand their product lines, which will help the allergy treatment market grow even more. Market participants are also undertaking a variety of strategic activities to expand their global footprint, with important market developments including new product launches, contractual agreements, mergers and acquisitions, higher investments, and collaboration with other organizations. To expand and survive in a more competitive and rising market climate, the allergy treatment industry must offer cost-effective items.

Manufacturing locally to minimize operational costs is one of the key business tactics used by manufacturers in the allergy treatment industry to benefit clients and increase the market sector. In recent years, the allergy treatment industry has offered some of the most significant advantages. Major players in the allergy treatment market, including Akorn, Incorporated (US), Pfizer Inc. (US), GlaxoSmithKline plc (UK), Novartis AG (Switzerland), Mylan N.V. (US), Teva Pharmaceutical Industries Ltd. (Israel), Sanofi (France), Boehringer Ingelheim International GmbH. (Germany), AstraZeneca (UK), Johnson & Johnson Private Limited (US), Bayer AG (Germany), Merck & Co., Inc. (US), and others are attempting to increase market demand by investing in research and development operations.

Alcon, a global leader in eye care, stands at the forefront of the industry with a rich history dating back to 1945. Headquartered in Geneva, Switzerland, and Fort Worth, Texas, USA, Alcon operates independently after its separation from Novartis in 2019. In July 2020, Alcon announced the U.S. Food and Drug Administration (FDA) approval of the OTC switch of Pataday once daily relief extra strength. Pataday Once Daily Comfort Extra Strength (olopatadine 0.7%) is the first and only eye allergy itch drop available in the United States that provides full 24-hour relief without a prescription.

Bausch Health Companies Inc., headquartered in Laval, Quebec, Canada, is a multinational pharmaceutical company committed to improving the health and well-being of patients globally. Formerly known as Valeant Pharmaceuticals International, Inc., the company underwent a name change in 2018 to Bausch Health Companies Inc. In March 2021, Bausch Health Companies Inc. and Glenmark Pharmaceuticals entered into an exclusive licensing agreement for the commercialization of Glenmark's innovative nasal spray RYALTRIS, under review by Health Canada.

Key Companies in the allergy treatment market include

• Akorn, Incorporated (US)


• Pfizer Inc. (US)


• GlaxoSmithKline plc (UK)


• Novartis AG (Switzerland)


• Mylan N.V. (US)


• Teva Pharmaceutical Industries Ltd. (Israel)


• Sanofi (France)


• Boehringer Ingelheim International GmbH. (Germany)


•  AstraZeneca (UK)


• Johnson & Johnson Private Limited (US)


• Bayer AG (Germany)


• Merck & Co., Inc. (US)

Allergy Treatment Industry Developments

October 2019: Allergan PLC announced the launch of three new over-the-counter (OTC) Refresh Relieva products. Refresh Relieva, Refresh Relieva PF (preservative-free) multidose, and Refresh Relieva for Contacts.

March 2018: Dr. Reddy's Laboratories launched levocetirizine dihydrochloride tablets, used for relieving allergies, in the U.S. Dr. Reddy's Laboratories said it had launched 'levocetirizine dihydrochloride tablets USP, 5 mg, an over-the-counter therapeutic equivalent generic version of UCB's Xyzal allergy tablets’ approved by the US Food and Drug Administration (FDA).

Allergy Treatment Market Segmentation

Allergy Treatment Type Outlook

• Eye Allergy


• Rhinitis


• Asthma


• Skin Allergy


• Food Allergy


• Other Allergies

Allergy Treatment treatment Outlook

• Anti-allergy Drugs


• Immunotherapy

Allergy Treatment Regional Outlook

• North America
  
  
  
  • US
  
  
  • Canada
  
  
  
  


• Europe
  
  
  
  • Germany
  
  
  • France
  
  
  • UK
  
  
  • Italy
  
  
  • Spain
  
  
  • Rest of Europe
  
  
  
  


• Asia-Pacific
  
  
  
  • China
  
  
  •  Japan
  
  
  •  India
  
  
  •  Australia
  
  
  •  South Korea
  
  
  • Australia
  
  
  •  Rest of Asia-Pacific
  
  
  
  


• Rest of the World
  
  
  
  • Middle East
  
  
  • Africa
  
  
  • Latin America